| Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019 | 561 | 2019 |
| Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016 | 460 | 2016 |
| Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ... The Lancet Neurology 19 (4), 307-316, 2020 | 378 | 2020 |
| Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis S Simpson-Yap, E De Brouwer, T Kalincik, N Rijke, JA Hillert, C Walton, ... Neurology 97 (19), e1870-e1885, 2021 | 253 | 2021 |
| Defining reliable disability outcomes in multiple sclerosis T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ... Brain 138 (11), 3287-3298, 2015 | 227 | 2015 |
| Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ... Annals of neurology 80 (1), 89-100, 2016 | 224 | 2016 |
| Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review T Kalincik Neuroepidemiology 44 (4), 199-214, 2015 | 217 | 2015 |
| Sex as a determinant of relapse incidence and progressive course of multiple sclerosis T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ... Brain 136 (12), 3609-3617, 2013 | 216 | 2013 |
| Thalamic atrophy is associated with development of clinically definite multiple sclerosis R Zivadinov, E Havrdová, N Bergsland, M Tyblova, J Hagemeier, Z Seidl, ... Radiology 268 (3), 831-841, 2013 | 201 | 2013 |
| Treatment decisions in multiple sclerosis—insights from real-world observational studies M Trojano, M Tintore, X Montalban, J Hillert, T Kalincik, P Iaffaldano, ... Nature Reviews Neurology 13 (2), 105-118, 2017 | 199 | 2017 |
| Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ... Annals of Neurology 77 (3), 425-435, 2015 | 192 | 2015 |
| Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ... The Lancet Neurology 16 (4), 271-281, 2017 | 182 | 2017 |
| Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis D Ontaneda, E Tallantyre, T Kalincik, SM Planchon, N Evangelou The Lancet Neurology 18 (10), 973-980, 2019 | 177 | 2019 |
| Cross cultural validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the brief international cognitive assessment for multiple … JB Dusankova, T Kalincik, E Havrdova, RHB Benedict The Clinical Neuropsychologist 26 (7), 1186-1200, 2012 | 164 | 2012 |
| Fingolimod after natalizumab and the risk of short-term relapse VG Jokubaitis, V Li, T Kalincik, G Izquierdo, S Hodgkinson, R Alroughani, ... Neurology 82 (14), 1204-1211, 2014 | 158 | 2014 |
| Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review B Merkel, H Butzkueven, AL Traboulsee, E Havrdova, T Kalincik Autoimmunity reviews 16 (6), 658-665, 2017 | 156 | 2017 |
| Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis A He, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, ... JAMA neurology 72 (4), 405-413, 2015 | 132 | 2015 |
| Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years R Zivadinov, N Bergsland, O Dolezal, S Hussein, Z Seidl, MG Dwyer, ... American Journal of Neuroradiology 34 (10), 1931-1939, 2013 | 131 | 2013 |
| Towards personalized therapy for multiple sclerosis: prediction of individual treatment response T Kalincik, A Manouchehrinia, L Sobisek, V Jokubaitis, T Spelman, ... Brain 140 (9), 2426-2443, 2017 | 129 | 2017 |
| Risk of relapse phenotype recurrence in multiple sclerosis T Kalincik, K Buzzard, V Jokubaitis, M Trojano, P Duquette, G Izquierdo, ... Multiple Sclerosis Journal 20 (11), 1511-1522, 2014 | 119 | 2014 |
